Boston Millennia Partners
LifeScan Partners with Cecelia Health to Provide Personalized Diabetes Health Management Coaching for OneTouch® Consumers
11.01.20
LifeScan, a world leader in blood glucose monitoring, serving 20 million people with diabetes and the maker of the iconic OneTouch® brand products, and Cecelia Health, one of the nation's most scalable clinical coaching and telehealth companies focused on diabetes and other chronic disease management, today announced a partnership to deliver best-in-class, live, personalized coaching from Cecelia Health's Certified Diabetes Care and Education Specialists through our OneTouch Reveal app beginning November 2020. Read Full Release
Boston Millennia Partners
STUDY IN NATURE MEDICINE SHOWS SUPERIOR OUTCOMES FOR PATIENTS IN LLS’S PARADIGM-SHIFTING BEAT AML CLINICAL TRIAL
10.26.20
Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal. The Beat AML trial achieved its primary endpoint by showing genomic analysis of the leukemia cells to identify AML subtypes can be completed within an unprecedented seven days, giving patients, caregivers and their doctors ample time to make a more personalized treatment decision without risking the patient’s chance for survival. Read Full Release
Boston Millennia Partners
Three NJ Startups Compete in Latest TechUnited:NJ STARTUP SHOWDOWN
09.22.20
Three tech startups from various parts of the Garden State competed in a Startup Showdown last week that focused on real-world data and evidence collection. The Startup Showdowns are presented by TechUnited:NJ (New Brunswick) and Tech Council Ventures (Summit) and hosted by Jasmine Hoffman. Pitching were Daniel Ferrara, founder and CEO of Roseland-based WellCare Today; Luke Malanga, COO of Cedar Knolls-based DataBiologics; and Kirsten Hund Blair, cofounder and CEO of Princeton-based Lambent Data. The investors who gave feedback were: Mark Kolb, entrepreneur in residence, Tech Council Ventures, who focuses on the healthcare industry; Steven Cohen, partner, Morgan Lewis (Philadelphia), who is chair of the Morgan Lewis emerging business and technology practice and an angel investor; and Ren Roome, principal, Boston Millennia Partners. The complete video of the program can be found here. For this episode, Lambent Data took home the audience choice award. Read Full Release
Stay up to date with COTA’s Real World Talk Podcast
09.16.20
The Evolving Relationship Between Real World Data and Clinical Trials with Nancy Dreyer and C.K. Wang In this episode of Real World Talk, host Zoe Li talks to Nancy Dreyer, Chief Scientific Officer of IQVIA, and COTA’s own Chief Medical Officer, Dr. C.K. Wang. They discuss the interactions between real world data and clinical trials, and how the two approaches can complement each other. They also look at why the Lancet retracted a large study into the use of hydroxychloroquine to treat COVID-19 in June, after questions were raised about its curation and application of real world data. Read Full Release
Boston Millennia Partners
Digital Diagnostics, formerly IDx, Expands Global Impact of Healthcare Autonomous AI with Acquisition of 3Derm Systems, Inc.
08.19.20
Healthcare access and inequity challenges have been exacerbated by the COVID-19 pandemic; members of at-risk populations around the world are increasingly delaying important specialist care. Today Digital Diagnostics Inc., a pioneering global healthcare autonomous artificial intelligence (AI) company formerly known as IDx, announces it has acquired 3Derm Systems, Inc. of Boston, MA. This acquisition makes Digital Diagnostics the global leader in healthcare autonomous AI, where it is the sole holder of autonomous AI healthcare systems that are De Novo authorized by the U.S. Food & Drug Administration (FDA), enabling the company to close more care gaps widened by COVID-19. Read Full Release
IBM Watson Health and OrbitalRX to Launch Integrated Solution to Assist Hospital Pharmacy Providers in Managing Drug Shortages
09.01.20
IBM (NYSE: IBM) Watson Health and OrbitalRX® today announced a strategic collaboration that aims to help address the emerging drug shortage crisis. The companies are combining OrbitalRX's Drug Shortage Management Platform and IBM® Micromedex® into one unified solution called "OrbitalRX and Micromedex," designed to create a single source for healthcare providers and pharmacy teams to access evidence-based treatment information alongside a hospital's current drug inventory status and drug sourcing options. This one solution aims to quickly analyze the supply chain and identify clinical alternatives for drugs that are in short supply. Read Full Release
medaptus Celebrates 20 Years of Health Technology Innovation
08.23.20
For 20 years medaptus has applied information technology to solve problems that are common and costly to healthcare organizations. To mark its twentieth anniversary, the company recently provided an update on its extensive technology capabilities grounded in interoperability. Read Full Release
Boston Millennia Partners
Digital Diagnostics, formerly IDx, Expands Global Impact of Healthcare Autonomous AI with Acquisition of 3Derm Systems, Inc.
08.23.20
Healthcare access and inequity challenges have been exacerbated by the COVID-19 pandemic; members of at-risk populations around the world are increasingly delaying important specialist care. Today Digital Diagnostics Inc., a pioneering global healthcare autonomous artificial intelligence (AI) company formerly known as IDx, announces it has acquired 3Derm Systems, Inc. of Boston, MA. This acquisition makes Digital Diagnostics the global leader in healthcare autonomous AI, where it is the sole holder of autonomous AI healthcare systems that are De Novo authorized by the U.S. Food & Drug Administration (FDA), enabling the company to close more care gaps widened by COVID-19. Read Full Release
Boston Millennia Partners
EY Announces David Weingard of Cecelia Health as an Entrepreneur Of The Year® 2020 New York Award Finalist
08.19.20
Ernst & Young LLP (EY US) has announced that David Weingard, CEO and Founder of Cecelia Health, was named an Entrepreneur Of The Year® 2020 New York Award finalist. Now in its 34th year, the Entrepreneur Of The Year program honors entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses that transform our world. David was selected as one of the finalists by a panel of independent judges comprising former winners and business leaders from multiple industries. Read Full Release
Boston Millennia Partners
Cecelia Health Completes $13 Million Series B Financing to Transform Lives of People Living with Diabetes and Other Chronic Conditions
08.13.20
Cecelia Health, a leading technology-enabled diabetes and other chronic disease management company, announced today it has completed a $13 million Series B funding round. The investment was co-led by Rittenhouse Ventures and Endo Investors, and includes investments from Boston Millennia Partners, SustainVC, G100 Capital, and others. The funding will enable the company to accelerate and further scale the adoption of the company's technology enabled coaching and telemedicine solutions and expand Cecelia Health’s digital health capabilities. Read Full Release
COTA Supports FDA Assessment of Real-World Data through Membership in COVID-19 Evidence Accelerator
06.10.20
COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, is pleased to announce a number of initiatives that are bringing enhanced understanding of COVID-19 in near real-time. Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network. Read Full Release
2020 MedTech Breakthrough Awards Recognize COTA as the Best Overall Medical Data Solution Provider
05.18.20
Boston, MA – May 18, 2020 – COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, is pleased to announce that MedTech Breakthrough has named COTA as a winner in the fourth annual MedTech Breakthrough Awards program for the “Best Overall Medical Data Solution Provider" award. The MedTech Breakthrough Awards recognize the top companies, people, platforms, and products in various industries including health, fitness, and medi Read Full Release
BC Platforms and Kaiser Permanente Win 2020 Microsoft Health Innovation Award for Precision Medicine Collaboration
05.19.20
BC Platforms and Kaiser Permanente today announced they are winners of the 2020 Microsoft Health Innovation Award in the Reimagine Health Category for enabling a unique way of pairing clinical and genomic data on the same platform to advance precision medicine capabilities. Read Full Release
Reveleer COVID-19 Business Continuity Update
04.01.20
Dear friends, As the world continues to rapidly change around us due to Coronavirus (COVID-19), we wanted to reach out to our partners, and prospective partners, to let you know what to expect from Reveleer during this challenging time.First and foremost, our thoughts go out to those who have been directly impacted by COVID-19 and those working on the front lines to treat and control the spread of illness.... Read Full Release
Introducing the BBJ’s Fast 50, The Region’s Fastest Growing Companies
04.08.20
The BosBizJournal has recognized COTA on its 2020 Fast 50 list! We are proud to be one of the fastest-growing private companies in MA this year & are committed to continuing on this path as we transform #cancer care. Congrats to all companies. https://bit.ly/2Xi1IlI #BBJFAST50 Read Full Release
Forefront Telecare Launches Phase 2 of COVID-19 Response for Rural Hospitals
04.09.20
NASHVILLE, Tenn., April 9, 2020 (Newswire.com) - Forefront Telecare, Inc. (Forefront), the leader in providing behavioral telehealth to seniors and other vulnerable adults in rural communities across the United States, announced today the next phase of its #RuralHealthSTRONG COVID-19 Response Program. As part of this program, Forefront is offering behavioral telehealth carts with secure, HIPAA-compliant video conferencing at no-cost to hundreds of rural hospitals nationwide. This proven platform has already been deployed by Forefront to over 200 facilities across the country. Read Full Release
MedAptus Again Leads KLAS Mobile Charge Capture Rankings
02.04.20
The annual "Best in KLAS" report is out and for the tenth time since 2011, medaptus has earned a top ranking, this year in the Mobile Charge Capture category. The "2020 Best in KLAS Awards: Software & Services" names the top-performing healthcare IT and services companies based on customer feedback obtained in 2019. This latest award recognizes the performance of medaptus' charge capture technology which enables efficient, accurate, and complete coding and billing. Beyond the software's ability to "capture" a charge, a robust rules engine and interface gateway enable real-time charge management and reconciliation activities, regardless of charge source. This unique automation replaces manual processes with intelligence such as work queues that route charge data based on exception. This approach expedites the billing cycle and with less administrative effort.  Read Full Release
Reveleer
Boston Millennia Partners Leads Investment in Reveleer, Inc.
01.21.19
Boston Millennia Partners IV is pleased to announce its investment in Reveleer, Inc. as part of a growth equity financing round. Reveleer is a healthcare software and services company that empowers health insurance companies to take control of their risk adjustment and quality improvement programs. The Reveleer software platform enables insurers to independently execute and manage every aspect of provider outreach, health record retrieval, coding, abstraction, and reporting. Leveraging its technology, proprietary data sets, and subject matter expertise, Reveleer also provides record retrieval and review services to support financial performance and improved member outcomes. As value-based contracts expand and the Medicare Advantage population continues to grow, the company is well positioned to be a leader in risk adjustment and quality analysis software. Click below to read on. Read Full Release
Boston Millennia Partners
TUCK STUDENTS “VENTURE” TO BOSTON
12.10.19
Thanks to the initiative of Center for Private Equity and Venture Capital Executive Director, Jim Feuille D’79, who called everyone to attention from the dining booth seat, Brodie Stone T’20 and Ross Klosterman T’20 pitched their company, UnifiHealth, which is focusing on reimagining health benefits for small businesses. After an evening of socializing, we had a full Friday of scheduled stops at Bain Capital Ventures, Boston Millennia Partners, Charles River Ventures, Openview Venture Partners, Flare Capital, and Green D Ventures. Read Full Release
COTA Genomic Profiling Study Released
12.11.19
A retrospective review of the COTA Real World Data (RWD) database was performed to identify patients with pathologically confirmed metastatic colon cancer (mCC) diagnosed between January 1, 2013 and December 1, 2017. Although guidelines recommend molecular testing for patients with mCRC, the current study included patients with mCC and excluded rectal cancer cases. At the time of data extraction, the COTA database included demographic, diagnostic, treatment, and quality-of-care information for patients with colon cancer abstracted from the electronic health records from 23 practices including 258 oncologists in Arkansas, Maryland, Michigan, New Jersey, New York, and Tennessee who contribute data under Business Associate Agreements. All data were de-identified to be compliant with Health Insurance Portability and Accountability Act and Office of Health Promotion Research regulations for purposes of secondary research use. The structure of the COTA database has been reviewed by the Western Institutional Review Board and has been deemed exempt from patient informed consent. Read Full Release